A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the effects of administration of VX-745 for 12 weeks on amyloid plaque
burden in Alzheimer's disease (AD). Subjects who meet entry criteria will undergo 11C-PiB
(Carbon-11-labeled Pittsburgh Compound B) positron emission tomography (PET) at baseline and
after 45 days of dosing with VX-745. Cognitive testing will also be conducted at baseline and
day 45.